Trial Profile
Second Line Erlitinib Combination With Gemcitabine Cisplatinum in Non-small Cell Lung Cancer Patients Who Harbored EGFR Sensitive Mutation Developed Resistance After First Line TKI Treatment
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Dec 2023
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Cisplatin; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 25 Dec 2023 Planned End Date changed from 12 Dec 2023 to 12 Dec 2025.
- 25 Dec 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 28 Feb 2022 Planned End Date changed from 1 Dec 2020 to 12 Dec 2023.